Santiago Viteri

Santiago Viteri

UNVERIFIED PROFILE

Are you Santiago Viteri?   Register this Author

Register author
Santiago Viteri

Santiago Viteri

Publications by authors named "Santiago Viteri"

Are you Santiago Viteri?   Register this Author

56Publications

2431Reads

12Profile Views

Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer.

Lung Cancer 2019 Jul 13;133:117-122. Epub 2019 May 13.

Medical Oncology Department, Rosell Oncology Institute (IOR), Dexeus University Hospital, Quironsalud Group, C/ Sabino Arana 5-19, 08028, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.05.010DOI Listing
July 2019

Tumor mutational burden as predictive factor of response to immunotherapy.

Transl Lung Cancer Res 2018 Dec;7(Suppl 4):S358-S361

Dr. Rosell Oncology Institute (IOR), Dexeus University Hospital, Quironsalud Group, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2018.10.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328696PMC
December 2018

Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.

J Thorac Oncol 2018 09 8;13(9):1324-1337. Epub 2018 May 8.

Instituto Oncológico Dr. Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Catalan Institute of Oncology and Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.04.030DOI Listing
September 2018

Activation of viral defense signaling in cancer.

Ther Adv Med Oncol 2018 29;10:1758835918793105. Epub 2018 Aug 29.

Rosell Oncology Institute (IOR), Dexeus University Hospital, Quironsalud Group, Barcelona, Spain Rosell Oncology Institute (IOR), Sagrat Cor University Hospital, Quironsalud Group, Barcelona, Spain Catalan Institute of Oncology, Germans Trias I Pujol University Hospital, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918793105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116077PMC
August 2018

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.

EBioMedicine 2018 03 5;29:112-127. Epub 2018 Feb 5.

Pangaea Oncology, Laboratory of Molecular Biology, Coyote Reserach Group, Quirón-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2018.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925453PMC
March 2018

An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs).

Transl Lung Cancer Res 2018 Feb;7(Suppl 1):S1-S4

Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2017.12.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835633PMC
February 2018

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).

Ther Adv Med Oncol 2018 9;10:1758834017745012. Epub 2018 Jan 9.

Instituto Oncológico Dr Rosell (IOR), University Hospital General de Catalunya, Sant Cugat del Vallès, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017745012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784559PMC
January 2018

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.

Ther Adv Med Oncol 2018 18;10:1758834017749748. Epub 2018 Jan 18.

Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017749748DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784541PMC
January 2018

Liquid Biopsy in Non-Small Cell Lung Cancer.

Front Med (Lausanne) 2016 23;3:69. Epub 2016 Dec 23.

Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2016.00069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179978PMC
December 2016

mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.

Transl Lung Cancer Res 2016 Oct;5(5):511-516

Pangaea Biotech, Laboratory of Oncology, Quirón Dexeus University Hospital, 08028 Barcelona, Spain;; Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, 08028 Barcelona, Spain;; Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Crta de Canyet s/n, 08016 Badalona, Spain;; Autonomous University of Barcelona (UAB), Campus Can Ruti, Crta de Canyet s/n, 08016 Badalona, Spain;; Molecular Oncology Research (MORe) Foundation, 08028 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2016.10.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099515PMC
October 2016

Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients.

Transl Lung Cancer Res 2016 Oct;5(5):525-531

Pangaea Biotech, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain;; Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain;; Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain;; Autonomous University of Barcelona (UAB), Campus Can Ruti, Badalona, Spain;; Molecular Oncology Research (MORe) Foundation, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2016.09.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099519PMC
October 2016

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.

Melanoma Res 2015 Dec;25(6):486-95

aTranslational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital bPangaea Biotech S.L cHospital Vall d'Hebron dCatalan Institute of Oncology, Hospital Germans Trias i Pujol Badalona eMORe Foundation, Barcelona fHospital Central Asturias, Oviedo gPivotal SL, Madrid hCUN, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000187DOI Listing
December 2015

Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity.

Transl Lung Cancer Res 2015 Dec;4(6):721-7

1 Medical Oncology, Department of Medicine, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 2 Pangaea Biotech, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain ; 4 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 5 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 6 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.10.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700230PMC
December 2015

Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.

Transl Lung Cancer Res 2015 Dec;4(6):728-42

1 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 2 Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain ; 3 Pangaea Biotech, Barcelona, Spain ; 4 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain ; 5 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 6 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.12.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700220PMC
December 2015

Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer.

Transl Lung Cancer Res 2015 Dec;4(6):756-62

1 Instituto Oncológico Dr Rosell, Quirón-Dexeus University Hospital, Barcelona, Spain ; 2 Instituto Nacional de Cancerología, México City, México.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.12.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700219PMC
December 2015

Melanoma: oncogenic drivers and the immune system.

Ann Transl Med 2015 Oct;3(18):265

1 Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain ; 2 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 3 Pangaea Biotech, Quirón Dexeus University Institute, Barcelona, Spain ; 4 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 5 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina 98122, Italy ; 6 Instituto Oncológico de Córdoba, Córdoba, Argentina ; 7 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 8 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2305-5839.2015.08.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630557PMC
October 2015

Other targeted drugs in melanoma.

Ann Transl Med 2015 Oct;3(18):266

1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2305-5839.2015.08.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630555PMC
October 2015

Advances in immunotherapy for treatment of lung cancer.

Cancer Biol Med 2015 Sep;12(3):209-22

1 Albert Einstein Medical Center, Philadelphia 19141, USA ; 2 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona 08028, Spain ; 3 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina 98100, Italy ; 4 Pangaea Biotech S.L, Barcelona 08028, Spain ; 5 Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona 08916, Spain ; 6 Fundación Molecular Oncology Research, Barcelona 08028, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7497/j.issn.2095-3941.2015.0032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607819PMC
September 2015

Targeting PD-1/PD-L1 in lung cancer: current perspectives.

Lung Cancer (Auckl) 2015 31;6:55-70. Epub 2015 Jul 31.

Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; Pangaea Biotech SL, Barcelona, Spain; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain; Fundación Molecular Oncology Research, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/LCTT.S55176DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217517PMC
July 2015

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints.

Cancer Biol Med 2015 Jun;12(2):79-86

1 Instituto Oncológico Dr Rosell, Quiron Dexeus University Hospital, Barcelona 08028, Spain ; 2 Pangaea Biotech, Barcelona 08028, Spain ; 3 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina 98122, Italy ; 4 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona 08916, Spain ; 5 Molecular Oncology Research (MORe) Foundation, Barcelona 08028, Spain ; 6 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti 08916, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7497/j.issn.2095-3941.2015.0029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493378PMC
June 2015

A critical question for cancer therapy: what new targets exist?

Transl Lung Cancer Res 2014 Dec;3(6):384-8

1 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 2 Molecular Oncology Research (MORe) Foundation, Sabino Arana 5-19, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Barcelona, Spain ; 4 Pangaea Biotech S.L, Sabino Arana 5-19, Barcelona, Spain ; 5 Institut Quìmic de Sarrià, Via Augusta 390, Barcelona, Spain ; 6 Fundació Institut de Investigació Germans Trias i Pujol, Badalona, Spain ; 7 Instituto Oncológico Nacional, Calle Gorgas, Ancon, Panamá

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2014.08.10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367674PMC
December 2014

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.

Expert Rev Anticancer Ther 2014 Jul 10;14(7):807-15. Epub 2014 Mar 10.

Instituto Oncológico Dr Rosell, Quirón-Dexeus Hospital Universitario, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2014.896210DOI Listing
July 2014

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.

Transl Lung Cancer Res 2014 Jun;3(3):122-30

1 Dr Rosell Oncology Institute, 2 Pangaea Biotech S.L, Quirón Dexeus University Hospital, Barcelona, Spain ; 3 Pivotal CRO, Madrid, Spain ; 4 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 5 Hospital General de Alicante, Alicante, Spain ; 6 CHU Limoges, Limoges, France ; 7 European Institute of Oncology (IEO), Milan, Italy ; 8 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2014.03.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367691PMC
June 2014

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.

Clin Cancer Res 2014 Apr 3;20(7):2001-10. Epub 2014 Feb 3.

Authors' Affiliations: Pangaea Biotech, Barcelona, Spain; Hospital Sant Pau, Barcelona, Spain; Hospital Vall d'Hebron, Barcelona, Spain; Molecular Oncology Research (MORe) Foundation, Barcelona, Spain; Pivotal, Madrid; Hospital General de Alicante, Alicante, Spain; Catalan Institute of Oncology, Badalona, Barcelona, Spain; Complejo Hospitalario Universitario, La Coruña, Spain; Centre François Baclesse, Caen, France; Drum Tower Hospital, Nanjing, China; Kyushu University, Fukuoka, Japan; Cancer Therapeutics Innovation Group, New York, New York, USA; and Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2233DOI Listing
April 2014

Predicting resistance by selection of signaling pathways.

Transl Lung Cancer Res 2014 Apr;3(2):107-15

1 Dr Rosell Oncology Institute, Quirón Dexeus University Institute, Barcelona, Spain ; 2 Pangaea Biotech, Quirón Dexeus University Institute, Barcelona, Spain ; 3 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 4 Molecular Cancer Research (MORe) Foundation, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2014.02.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367662PMC
April 2014

The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung.

Transl Lung Cancer Res 2013 Jun;2(3):172-9

Pangaea Biotech, Dexeus University Institute, Barcelona, Spain ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2013.01.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367598PMC
June 2013

BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.

Transl Lung Cancer Res 2013 Jun;2(3):244-50

Breakthrough Cancer Research Unit, Pangaea Biotech S.L, Barcelona, Spain ; Catalan Institute of Oncology, Badalona, Spain.

View Article

Download full-text PDF

Source
http://www.tlcr.org/article/view/1102
Publisher Site
http://dx.doi.org/10.3978/j.issn.2218-6751.2013.04.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367599PMC
June 2013

CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors.

Transl Lung Cancer Res 2013 Apr;2(2):65-71

Breakthrought Cancer Unit, Laboratory of Oncology, Pangaea Biotech, Dexeus University Hospital, Barcelona, Spain ; ; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://www.tlcr.org/article/view/1027
Publisher Site
http://dx.doi.org/10.3978/j.issn.2218-6751.2013.02.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369853PMC
April 2013

Evaluation of multiple serum markers in advanced melanoma.

Tumour Biol 2011 Dec 20;32(6):1155-61. Epub 2011 Aug 20.

Laboratory of Biochemistry, University Clinic of Navarra, Avd. Pio XII 36, Pamplona, 31008, Spain.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s13277-011-0218
Web Search
http://link.springer.com/10.1007/s13277-011-0218-x
Publisher Site
http://dx.doi.org/10.1007/s13277-011-0218-xDOI Listing
December 2011

Predictive biomarkers in the management of EGFR mutant lung cancer.

Ann N Y Acad Sci 2010 Oct;1210:45-52

Catalan Institue of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1749-6632.2010.05775.xDOI Listing
October 2010

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.

Expert Opin Pharmacother 2010 Jul;11(10):1683-93

Hospital Germans Trias i Pujol, Catalan Institute of Oncology, Medical Oncology Service, Ctra Canyet, s/n 08916 Badalona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14656566.2010.48
Publisher Site
http://dx.doi.org/10.1517/14656566.2010.482101DOI Listing
July 2010

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.

Curr Opin Oncol 2010 Mar;22(2):112-20

Catalan Institue of Oncology, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32833500d2DOI Listing
March 2010